title: [Study on effect of shenmai injection in protecting myocardium against ischemia-reperfusion injury in thrombolytic therapy with urokinase for acute myocardial infarction patients evaluated by 99mTc-MIBI myocardial imaging].
abstract: OBJECTIVE
  To evaluate the myocardial protecting effect of Shenmai injection (SMI) against ischemia/reperfusion injury in thrombolytic therapy with urokinase (UK) for acute myocardial infarction patients by 99mTc-MIBI myocardial imaging (SPECT).
  
  
  METHODS
  Five hundred and thirty-seven patients were randomly divided into two groups. The SMI group (n = 292) was treated with thrombolytic treatment plus SMI and the control group (n = 245) with thrombolytic treatment only. Single photon emission computerized tomography (SPECT) was carried out on the 7th day after thrombolysis to determine the ischemic myocardial area (IMA) and ejection fraction (EF) in both groups and compared.
  
  
  RESULTS
  The reperfusion rate of infarction related area (IRA) in the two groups was not different significantly (72.26% vs 72.65%, P > 0.05). The IMA in patients of the SMI group, no matter with or without reperfused IRA (211 cases and 81 cases) respectively, was significantly lower than that in the control group (178 cases and 67 cases) respectively, P < 0.01 and P < 0.05 respectively. The EF value in the SMI group was significantly higher than that in the control group (P < 0.01).
  
  
  CONCLUSIONS
  Using SMI in early stage of thrombolytic treatment in acute myocardial infarction could significantly reduce IMA and increase EF. SMI showed good protective effect against myocardial ischemia/reperfusion injury in thrombolytic treatment.
authors.affiliation: Weifang People's Hospital, Shandong 261041.
authors.forename: S P
authors.initials: SP
authors.lastname: Guo
authors.forename: Y Z
authors.initials: YZ
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015428:Myocardial Reperfusion Injury / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D019275:Radiopharmaceuticals; C009252:fructus schizandrae, radix ginseng, radix ophiopogonis drug combination; D017256:Technetium Tc 99m Sestamibi; D014568:Urokinase-Type Plasminogen Activator